Androgen Receptor Is Expressed in the Majority of Breast Cancer Brain Metastases and Is Subtype-Dependent
Open Access
Abstract
We aimed to evaluate the expression of the “targetable” androgen receptor (AR) in breast cancer brain metastases (BrM). An established, retrospective 57-patient cohort with metastatic breast cancer who underwent surgery for BrM at the Sunnybrook Odette Cancer Centre between 1999–2013 was studied. AR expression in BrM samples was assessed in triplicate using immunohistochemistry (IHC). AR positive status was defined as nuclear AR expression ≥ 10% by IHC using the SP107 antibody. The median age of patients was 52 years (range 32–85 years). 28 (49%) of BrM were HER2+, 17 (30%) were hormone receptor positive (HR+)/HER2−, and 12 (21%) were triple negative breast cancers (TNBCs). 56% (n = 32/57) of BrM were AR positive, and median AR expression was 20% (CI 1.6–38.3%). AR expression was different across breast cancer subtypes; AR was most frequently expressed in HER2+ (n = 21/28), followed by HR+/HER2− (n = 9/17), and lowest in TNBC (n = 2/12) BrM (p = 0.003). Patients with AR positive versus AR negative BrM had similar overall survival (12.5 vs. 7.9 months, p = 0.6), brain-specific progression-free survival (8.0 vs. 5.1 months, p = 0.95), and time from breast cancer diagnosis to BrM diagnosis (51 vs. 29 months, p = 0.16). AR is expressed in the majority of breast cancer BrM and represents a potential therapeutic target.Keywords
This publication has 42 references indexed in Scilit:
- Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registryBreast Cancer Research and Treatment, 2013
- Expression of the Androgen Receptor and its Correlation with Molecular Subtypes in 980 Chinese Breast Cancer PatientsBreast Cancer: Basic and Clinical Research, 2011
- Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1The EMBO Journal, 2011
- Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health StudyLaboratory Investigation, 2011
- Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal WomenClinical Cancer Research, 2011
- Higher levels of GATA3 predict better survival in women with breast cancerHuman Pathology, 2010
- Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancersVirchows Archiv, 2010
- Expression of androgen receptors in primary breast cancerAnnals of Oncology, 2009
- GATA-3 Links Tumor Differentiation and Dissemination in a Luminal Breast Cancer ModelCancer Cell, 2008
- Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factorsThe Journal of Pathology, 1993